company background image
AROC

AroCell OM:AROC Stock Report

Last Price

kr0.51

Market Cap

kr117.0m

7D

-1.9%

1Y

-90.5%

Updated

30 Jun, 2022

Data

Company Financials +
AROC fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

AROC Stock Overview

AroCell AB (publ), a vitro diagnostics company, focuses on monitoring of hematological malignancies, breast cancer, and other solid tumors.

AroCell Competitors

Price History & Performance

Summary of all time highs, changes and price drops for AroCell
Historical stock prices
Current Share Pricekr0.51
52 Week Highkr6.70
52 Week Lowkr0.41
Beta1.41
1 Month Change-5.38%
3 Month Change-4.67%
1 Year Change-90.54%
3 Year Change-81.92%
5 Year Change-89.80%
Change since IPO-84.55%

Recent News & Updates

Shareholder Returns

AROCSE Life SciencesSE Market
7D-1.9%-0.7%-0.06%
1Y-90.5%-46.8%-22.4%

Return vs Industry: AROC underperformed the Swedish Life Sciences industry which returned -46.8% over the past year.

Return vs Market: AROC underperformed the Swedish Market which returned -22.4% over the past year.

Price Volatility

Is AROC's price volatile compared to industry and market?
AROC volatility
AROC Average Weekly Movement8.2%
Life Sciences Industry Average Movement8.3%
Market Average Movement7.4%
10% most volatile stocks in SE Market12.3%
10% least volatile stocks in SE Market4.7%

Stable Share Price: AROC is not significantly more volatile than the rest of Swedish stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: AROC's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
200020Anders Hultmanhttps://www.arocell.com

AroCell AB (publ), a vitro diagnostics company, focuses on monitoring of hematological malignancies, breast cancer, and other solid tumors. The company develops, manufactures, and sells AroCell TK 210 ELISA, an immunoassay kit for the determination of Thymidine Kinase 1 in human blood. It also offers TUBEX TF, a bacteriological rapid test for diagnosis of typhoid fever.

AroCell Fundamentals Summary

How do AroCell's earnings and revenue compare to its market cap?
AROC fundamental statistics
Market Capkr117.02m
Earnings (TTM)-kr59.43m
Revenue (TTM)kr19.72m

6.0x

P/S Ratio

-2.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
AROC income statement (TTM)
Revenuekr19.72m
Cost of Revenuekr25.88m
Gross Profit-kr6.16m
Other Expenseskr53.28m
Earnings-kr59.43m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

Aug 17, 2022

Earnings per share (EPS)-0.26
Gross Margin-31.21%
Net Profit Margin-301.34%
Debt/Equity Ratio0.0%

How did AROC perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is AROC undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for AROC?

Other financial metrics that can be useful for relative valuation.

AROC key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue1.5x
Enterprise Value/EBITDA-0.9x
PEG Ration/a

Price to Sales Ratio vs Peers

How does AROC's PS Ratio compare to its peers?

AROC PS Ratio vs Peers
The above table shows the PS ratio for AROC vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average7x
ALPH AlphaHelix Molecular Diagnostics
1.3xn/akr60.4m
ATANA Attana
17.4x9.4%kr149.8m
MAGLE Magle Chemoswed Holding
1.7xn/akr226.8m
ISAB Inhalation Sciences Sweden
7.8x47.5%kr64.8m
AROC AroCell
6x34.7%kr117.0m

Price-To-Sales vs Peers: AROC is good value based on its Price-To-Sales Ratio (6x) compared to the peer average (7x).


Price to Earnings Ratio vs Industry

How does AROC's PE Ratio compare vs other companies in the European Life Sciences Industry?

Price-To-Sales vs Industry: AROC is good value based on its Price-To-Sales Ratio (6x) compared to the Swedish Life Sciences industry average (6.7x)


Price to Sales Ratio vs Fair Ratio

What is AROC's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

AROC PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio6x
Fair PS Ratio4.6x

Price-To-Sales vs Fair Ratio: AROC is expensive based on its Price-To-Sales Ratio (6x) compared to the estimated Fair Price-To-Sales Ratio (4.6x).


Share Price vs Fair Value

What is the Fair Price of AROC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate AROC's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate AROC's fair value for valuation analysis.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate AROC's PEG Ratio to determine if it is good value.


Discover undervalued companies

Future Growth

How is AroCell forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

Future Growth Score

2/6

Future Growth Score 2/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


7.8%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: AROC is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: AROC is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: AROC is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: AROC's revenue (34.7% per year) is forecast to grow faster than the Swedish market (5.5% per year).

High Growth Revenue: AROC's revenue (34.7% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: AROC is forecast to be unprofitable in 3 years.


Discover growth companies

Past Performance

How has AroCell performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-24.9%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: AROC is currently unprofitable.

Growing Profit Margin: AROC is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: AROC is unprofitable, and losses have increased over the past 5 years at a rate of 24.9% per year.

Accelerating Growth: Unable to compare AROC's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: AROC is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (83.9%).


Return on Equity

High ROE: AROC has a negative Return on Equity (-21.65%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is AroCell's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: AROC's short term assets (SEK109.8M) exceed its short term liabilities (SEK17.2M).

Long Term Liabilities: AROC has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: AROC is debt free.

Reducing Debt: AROC had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: AROC has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: AROC has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 8.7% each year


Discover healthy companies

Dividend

What is AroCell current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate AROC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate AROC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if AROC's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if AROC's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as AROC has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

1.0yrs

Average management tenure


CEO

Anders Hultman (47 yo)

1.42yrs

Tenure

Mr. Anders Hultman, B.Sc., has been Chief Executive Officer at AroCell AB (publ) since January 11, 2021. Mr. Hultman served as Chief Financial Officer at AroCell AB (publ) since December 2018 until January...


Leadership Team

Experienced Management: AROC's management team is not considered experienced ( 1 years average tenure), which suggests a new team.


Board Members

Experienced Board: AROC's board of directors are not considered experienced ( 0.8 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: AROC insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 204.3%.


Top Shareholders

Company Information

AroCell AB (publ)'s employee growth, exchange listings and data sources


Key Information

  • Name: AroCell AB (publ)
  • Ticker: AROC
  • Exchange: OM
  • Founded: 2000
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: kr117.023m
  • Shares outstanding: 230.36m
  • Website: https://www.arocell.com

Number of Employees


Location

  • AroCell AB (publ)
  • Uppsala Business Park
  • Virdings allé 32 B
  • Uppsala
  • Uppsala County
  • 754 50
  • Sweden

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/06/30 00:00
End of Day Share Price2022/06/30 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.